Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656144 | 0.88 | POLB (0.47) | ENPP1AURKAPOLBHTTALDH1A1 | |
| SCHEMBL23762522 | 0.86 | ENPP1 (0.63) | ENPP1AURKAACHEBACE1TLR9 | |
| SCHEMBL30079917 | 0.86 | ENPP1 (0.63) | ENPP1AURKAACHEBACE1TLR9 | |
| SCHEMBL25656147 | 0.85 | ENPP1 (0.51) | ENPP1AURKAHTTALDH1A1NPSR1 | |
| SCHEMBL25656148 | 0.83 | ENPP1 (0.54) | ENPP1AURKAHTTALDH1A1NPSR1 | |
| SCHEMBL25656143 | 0.82 | ENPP1 (0.48) | ENPP1AURKAHTTALDH1A1NPSR1 | |
| SCHEMBL25656151 | 0.78 | ENPP1 (0.69) | ENPP1AURKA | |
| SCHEMBL15314918 | 0.77 | PRKDC (0.52) | ENPP1HTTALDH1A1NPSR1ACHE | |
| SCHEMBL25656113 | 0.77 | PRKDC (0.52) | ENPP1HTTALDH1A1NPSR1ACHE | |
| SCHEMBL25655997 | 0.77 | ENPP1 (0.65) | ENPP1AURKAALDH1A1TLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885AURKA 3497/4885POLB 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.